The retatrutide weight loss projection tool on this page provides researchers and clinicians with an evidence-based estimate of expected weight reduction based on published clinical trial dose-response data. Retatrutide weight loss projection models are derived directly from the TRIUMPH-1 Phase 3 trial conducted by Eli Lilly, which demonstrated unprecedented weight loss outcomes among investigational GLP-1/GIP/glucagon triple agonist compounds. This tool allows side-by-side comparison of retatrutide versus tirzepatide, offering a clear visualization of how each compound performs across different dosing protocols over time.

What Is the Retatrutide Weight Loss Projection Tool?

This interactive retatrutide weight loss projection calculator allows researchers to input subject parameters — including sex, height, starting weight, target weight, and weekly dose — and generate a visual timeline of projected weight reduction. The underlying model is calibrated against published dose-response curves from Phase 2 and Phase 3 clinical studies. Rather than providing a generic percentage figure, the retatrutide weight loss projection tool outputs a week-by-week graph that mirrors the actual weight trajectory observed in trial participants receiving the selected dose.

The tool currently models two research compounds: retatrutide and tirzepatide. Both are incretin-based peptides that have demonstrated substantial efficacy in published obesity research. Researchers studying retatrutide weight loss projection data can toggle between compounds to compare trajectories under matched dosing conditions, providing a meaningful basis for protocol planning and expected outcome estimation.

All projections are derived from clinical trial averages and represent population-level estimates. Individual responses will vary based on baseline metabolic rate, dietary behavior, physical activity, and genetic factors not captured in trial averages. This tool is intended exclusively for research and educational use.

How the Retatrutide Weight Loss Projection Model Works

The retatrutide weight loss projection model uses a sigmoidal dose-response function fitted to published weekly weight measurements from the TRIUMPH-1 trial (Eli Lilly, May 2026). Researchers studying this compound will recognize that the weight trajectory follows a characteristic curve: rapid initial loss in the first 8–12 weeks, a deceleration phase between weeks 12–36, and an apparent plateau phase beyond week 36 as participants approach their pharmacologically achievable nadir.

The model incorporates three dose tiers — Low, Medium, and Maximum — which correspond to the dosing arms evaluated in clinical research. For retatrutide, the maximum weekly dose evaluated in Phase 3 is 8 mg/week, administered subcutaneously. At this dose, TRIUMPH-1 data demonstrated mean weight reduction of approximately 28.3% from baseline, representing the highest weight loss percentage ever recorded in a Phase 3 obesity trial at the time of reporting. The retatrutide weight loss projection at lower doses (2 mg/week and 4 mg/week) showed proportionally reduced but still clinically meaningful reductions averaging 17–22%.

The calculator adjusts the projected absolute weight loss based on the subject's starting weight, providing personalized output in both pounds and kilograms. This approach is consistent with how researchers analyze individual-level data when extrapolating from population-level clinical trial results.

Retatrutide Mechanism of Action: Why the Projections Are So Steep

Understanding the retatrutide weight loss projection data requires an appreciation of why this compound produces greater weight reduction than prior GLP-1 receptor agonists. Retatrutide is a unimolecular triple agonist that simultaneously activates three receptor pathways: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonism differentiates retatrutide from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist), and is the primary pharmacological explanation for the steeper retatrutide weight loss projection curves observed in research models.

GLP-1 receptor activation suppresses appetite through central mechanisms involving the hypothalamus and brainstem, slows gastric emptying, and enhances insulin secretion in a glucose-dependent manner. GIP receptor co-activation potentiates the anorexigenic effects of GLP-1 and may also improve peripheral lipid metabolism. The addition of glucagon receptor agonism — unique to retatrutide among currently studied compounds — increases resting metabolic rate and promotes hepatic fat oxidation, contributing additional weight loss beyond what GLP-1/GIP dual agonism alone can achieve. Published data from Jastreboff et al. (2023) in the New England Journal of Medicine confirmed these mechanisms in Phase 2 dose-escalation studies, laying the groundwork for the Phase 3 projections reflected in this tool.

The glucagon receptor component also drives increased energy expenditure, which means that the retatrutide weight loss projection model must account for a dual mechanism of action: reduced caloric intake (via appetite suppression) combined with increased caloric expenditure (via elevated metabolic rate). This is why even when controlling for starting weight and dose, the retatrutide weight loss projection curves are steeper than those modeled for tirzepatide or semaglutide at comparable time points.

Retatrutide vs. Tirzepatide: Comparing Projected Weight Loss

The projection tool enables direct comparison of retatrutide vs tirzepatide weight loss trajectories. Understanding these differences is important for researchers designing protocols or reviewing the comparative efficacy literature.

The retatrutide weight loss projection data show a steeper early trajectory compared to tirzepatide, particularly in the first 24 weeks. Researchers interested in the comparative pharmacology of these compounds can explore the retatrutide vs tirzepatide comparison guide for a deeper analysis of mechanism, efficacy, and research protocol considerations. A broader comparison including semaglutide is also available in the semaglutide vs retatrutide vs tirzepatide guide.

Published Research Behind the Retatrutide Weight Loss Projection

The retatrutide weight loss projection model is grounded in published and presented clinical data from multiple trial phases. Researchers reviewing this tool should be familiar with the primary sources that inform the dose-response curves displayed.

The foundational Phase 2 data were published in the New England Journal of Medicine in July 2023. That study, known as the TRIUMPH Phase 2 trial, enrolled 338 adults with obesity and randomized them to placebo or one of five retatrutide doses ranging from 1 mg to 12 mg weekly for 24 weeks. The maximum dose group (12 mg/week) achieved mean weight reduction of 24.2% — a result that exceeded anything previously reported in a Phase 2 obesity trial. The full Phase 2 data from Jastreboff et al. are indexed on PubMed and represent the most comprehensive published dose-response dataset for retatrutide to date.

The TRIUMPH-1 Phase 3 trial (Eli Lilly, 2026) extended this work with a larger sample size, longer follow-up, and standardized 8 mg maximum dose protocol. The 28.3% mean weight reduction at the maximum dose over 48 weeks forms the anchor point for the retatrutide weight loss projection curves shown in this tool. This result is notable because it represents weight loss approximately equivalent to that achieved with bariatric surgery in some populations, according to comparative analyses published in metabolic disease literature. Additional context on these results is available in the retatrutide results research guide.

Researchers interested in the full pharmacological profile of retatrutide — including half-life, reconstitution protocols, and storage requirements — can consult the comprehensive retatrutide research guide for a thorough overview of the available data.

How to Interpret Your Retatrutide Weight Loss Projection

When using this retatrutide weight loss projection tool, researchers should apply appropriate statistical context to the outputs. Several key interpretive principles apply:

Population Averages, Not Individual Guarantees: The retatrutide weight loss projection represents the mean expected outcome for a subject matching the input parameters. Published clinical trial data consistently show a range of approximately ±8–12% around the mean weight reduction figure. Some subjects in TRIUMPH-1 achieved weight loss exceeding 35%, while others in the same dose group lost less than 15%.

No Dietary or Lifestyle Assumptions: The projection tool assumes no changes in dietary intake or physical activity beyond what was observed in the placebo-controlled trial setting, which typically involves modest dietary counseling. Real-world outcomes with caloric restriction and exercise may be substantially higher than what the retatrutide weight loss projection displays.

Dose Escalation Timeline: Clinical research protocols typically use a gradual dose escalation schedule over 16–24 weeks before reaching the maximum dose. The projection curves shown here represent steady-state dose exposure. Actual weight loss during the escalation phase may be slower than depicted, with acceleration once the maintenance dose is reached.

Plateau and Maintenance Phase: The retatrutide weight loss projection shows a flattening of the weight curve after approximately 32–40 weeks at maximum dose. This plateau is consistent with the observed clinical data and reflects the pharmacological set-point reached when appetite suppression and metabolic adaptation achieve equilibrium. Researchers should note that weight maintenance on the compound remains active — subjects who discontinue retatrutide in clinical trials typically regain weight, as documented in the weight regain literature for GLP-1 class compounds.

Research Protocol Considerations for Retatrutide

Researchers incorporating retatrutide into study protocols should be aware of key handling and preparation requirements that can affect compound stability and dose delivery accuracy. These factors are relevant to interpreting the retatrutide weight loss projection in the context of in-vivo preclinical models.

Retatrutide is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to use. Standard reconstitution protocols specify using sterile bacteriostatic water at a concentration of 1–2 mg/mL, though specific research protocols may vary. The reconstituted solution should be stored at 2–8°C and used within 28 days of preparation. Exposure to temperatures above 25°C or repeated freeze-thaw cycles can lead to peptide degradation and reduced biological activity. Researchers concerned about compound stability can consult the peptide storage guide for detailed temperature and handling recommendations.

For subcutaneous administration in preclinical research models, injection volumes should be calculated based on the reconstituted concentration and the desired dose per body weight (typically expressed in µg/kg for rodent studies). The NIH-indexed pharmacokinetic data for GLP-1/glucagon receptor agonists provides reference values for half-life and bioavailability parameters that researchers can apply when designing dosing schedules.

Purity verification is an essential step before initiating any research protocol. Researchers should review the certificate of analysis (CoA) for HPLC purity data, with research-grade retatrutide typically characterized at ≥98% purity by analytical HPLC. Mass spectrometry confirmation of molecular weight is also standard in peptide characterization protocols.

Frequently Asked Questions About Retatrutide Weight Loss Projection

Researchers and educators frequently ask the following questions about how to interpret and apply the retatrutide weight loss projection data presented on this page.

Q: How accurate is the retatrutide weight loss projection tool?
The projection is calibrated to the mean weight loss outcomes observed in published clinical trials, specifically TRIUMPH-1 Phase 3 and the Phase 2 NEJM study. It accurately reflects population-level averages but cannot predict individual outcomes. Variance of ±10% around the displayed value is consistent with observed trial data distributions. The tool is intended for research planning and educational visualization, not for clinical prediction in individual subjects.

Q: Can the retatrutide weight loss projection be compared directly to tirzepatide outcomes?
Yes, the tool allows direct side-by-side comparison. However, researchers should note that the trials used different endpoints, dose escalation schedules, and follow-up durations. TRIUMPH-1 for retatrutide used a 48-week endpoint with 8 mg/week maximum, while SURMOUNT-1 for tirzepatide used a 72-week endpoint with 15 mg/week maximum. Absolute comparisons should be interpreted with these methodological differences in mind.

Q: Does the retatrutide weight loss projection account for the glucagon receptor effect on metabolic rate?
The projection model is fitted to observed weight outcomes, which inherently capture all mechanisms of action — including the glucagon receptor-mediated increase in metabolic rate. The model does not separately quantify the contribution of each receptor pathway, but the overall effect is reflected in the steeper weight loss trajectory compared to dual agonists like tirzepatide.

Q: What does "retatrutide weight loss projection" show at the low dose tier?
At the low dose tier (approximately 2 mg/week), the retatrutide weight loss projection reflects Phase 2 trial data showing roughly 8–12% mean weight reduction over 24 weeks. This is meaningful for early-phase research protocols studying the dose-response relationship, but is substantially less than the maximum-dose projection of 28.3% over 48 weeks.

Safety Profile and Adverse Events in Retatrutide Research

Published clinical data from both Phase 2 and Phase 3 retatrutide studies document a consistent adverse event profile characteristic of GLP-1 class compounds. Understanding this profile is essential context for interpreting the retatrutide weight loss projection data, as adverse event-driven dose reductions or discontinuations can alter actual outcomes relative to the projected model.

Gastrointestinal adverse events are the most commonly reported, including nausea, vomiting, diarrhea, and constipation. In the Phase 2 NEJM study, nausea was reported in 47% of subjects receiving the 12 mg dose, compared to 13% in the placebo group. These events were predominantly mild to moderate in severity and were most frequent during the dose escalation phase. The incidence of gastrointestinal events declined substantially after week 12 as subjects reached their target maintenance dose. Researchers designing protocols that incorporate a retatrutide weight loss projection model should account for the possibility that dose reductions necessitated by gastrointestinal tolerability may shift actual outcomes toward the lower dose projections.

Injection site reactions were reported in approximately 15% of subjects and were uniformly mild and transient. Heart rate increases averaging 7–9 beats per minute were documented at the 12 mg dose level, consistent with glucagon receptor-mediated sympathetic activation. This is a distinguishing feature of the retatrutide safety profile compared to dual GLP-1/GIP agonists, where heart rate effects are less pronounced. Researchers monitoring cardiovascular parameters in preclinical models should incorporate this expected heart rate elevation when designing endpoints.

Hypoglycemia risk in subjects without diabetes was low across all dose tiers in published retatrutide research, with severe hypoglycemia not reported in the Phase 2 study. The glucose-dependent mechanism of GLP-1 receptor activation provides inherent protection against hypoglycemia in euglycemic subjects, a pharmacological advantage relevant to research protocol design.

Using the Retatrutide Weight Loss Projection for Research Planning

The retatrutide weight loss projection tool on this page serves as a practical resource for researchers designing obesity intervention studies, preclinical protocols, and comparative efficacy analyses. When used in conjunction with the published clinical trial literature, the projection model allows investigators to set realistic outcome expectations, power their studies appropriately, and communicate expected results to stakeholders.

For researchers comparing retatrutide weight loss projection outcomes against other metabolic research compounds, the internal comparison tool provides immediate visual context. Researchers who need additional background on the broader landscape of peptide-based weight loss research can review the best peptides for weight loss research guide, which covers multiple compound classes and their published efficacy data.

The retatrutide weight loss projection should always be interpreted alongside purity documentation, reconstitution records, and dosing logs. The accuracy of any in-vivo projection depends on the fidelity of the administered dose relative to the nominal dose — a parameter that is entirely dependent on compound purity, proper reconstitution technique, and accurate volumetric delivery. Reference the FDA guidance on peptide analytical characterization for standards applicable to research-grade compound preparation.

All PSPeptides products are sold exclusively for research and laboratory use.